ÂÜÀòÂÒÂ×

Reinout Hesselink, PhD, is an experienced expert in the Advanced Therapy Medicinal Products (ATMP) field, currently serving as the Owner of R.H. Cell Therapy Consulting since October 2020, providing consultancy in strategy, quality, and regulatory aspects of cell and gene therapies. Additional roles include Vice President of Process Development and CMC/Regulatory at Pan Cancer T and ATMP Process Architect at Antleron, where Reinout focuses on scalable manufacturing processes. Previously, positions included Chief Technology Officer at Stimuliver, Certified Senior Auditor at SQA Services, Quality Manager at CiMaas BV, and Director of Process Development at ExCellThera. Earlier experience includes consulting at eXmoor Pharma Concepts and business development management at BioNTech IMFS. Reinout Hesselink holds a PhD in Skeletal Muscle Damage and Regeneration and a Master's degree in Movement Sciences from Maastricht University.